JAPANESE - Skin Toxicity Evaluation Protocol With Panitumumab as 3rd line treatment for Colorectal Cancer(J-STEPP),(HGCSG1001)

Phase 2

• Conditions: unresectable advanced colorectal cancer

• Registration Number: JPRN-UMIN000004883
• Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group(HGCSG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-01-15
• Study Completion: 2015-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

Not provided

Exclusion Criteria

(a)Patient who have previous history of hypersensitivity in Panitumumab and other medicines (b)The KRAS mutation type. (c)pregnant woman or possibility pregnancy while suckling walking (d)Patient with interstitial pneumonia (e)the anti-EGFR antibody had been administered so far. (f)Patient who is administering bevacizumab (g)Patient who is judged improper by Doctor.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverce event of skin toxicity (>= grade2) during the 6 weeks from treatment started

Secondary Outcome Measures

Name	Time	Method
Time to appearance of skin toxicity(each grade) ,Safety,Progression-free Survival, Overall Survival,Time-to-treatment-failure,Overall Response Rate